Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2014 Jan 14;28(2):257-65.
doi: 10.1097/QAD.0000000000000078.

Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals

Affiliations
Multicenter Study

Cause-specific mortality among HIV-infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV-uninfected individuals

Nikolas Wada et al. AIDS. .

Abstract

Objectives: To compare the proportion, timing and hazards of non-AIDS death and AIDS death among men and women who initiated HAART at different CD4 cell counts to mortality risks of HIV-uninfected persons with similar risk factors.

Design: Prospective cohort studies.

Methods: We used parametric mixture models to compare proportions of AIDS and non-AIDS mortality and ages at death, and multivariable Cox models to compare cause-specific hazards of mortality, across levels of CD4 cell count at HAART initiation (≤200 cells/μl: 'late', 201-350 cells/μl: 'intermediate', >350 cells/μl: 'early') and with HIV-uninfected individuals from the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study. We used multiple imputation methods to address lead-time bias in sensitivity analysis.

Results: Earlier initiators were more likely to die of non-AIDS causes (early: 78%, intermediate: 74%, late: 49%), and at older ages (median years 72, 69, 66), relative to later initiators. Estimated median ages at non-AIDS death for each CD4 cell count category were lower than that estimated for the HIV-uninfected group (75 years). In multivariable analysis, non-AIDS death hazard ratios relative to early initiators were 2.15 for late initiators (P < 0.01) and 1.66 for intermediate initiators (P = 0.01); AIDS death hazard ratios were 3.26 for late initiators (P < 0.01) and 1.20 for intermediate initiators (P = 0.28). Strikingly, the adjusted hazards for non-AIDS death among HIV-uninfected individuals and early initiators were nearly identical (hazard ratio 1.01). Inferences were unchanged after adjustment for lead-time bias.

Conclusion: Results suggest the possibility of reducing the risk of non-AIDS mortality among HIV-infected individuals to approximate that faced by comparable HIV-uninfected individuals.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Cause-specific mortality by CD4+cell count at HAART initiation, compared to HIV-negative individuals (a,b) Probability density functions for non-AIDS death (a) and AIDS death (b), stratified by CD4+ cell count at HAART initiation. Percentages represent proportion of all-cause mortality. (c,d) Differences in age at non-AIDS death (c) and AIDS death (d) by percentile, stratified by CD4+cell count at HAART initiation. Reference category for (c) is HIV-negative. Reference category for (d) is CD4+ cell count >350 cells/μl at HAART initiation. For example, at 50% decreased in Fig. 1c, the value of the blue dashed line (−3.0) represents the median age at non-AIDS death for the early initiators (72.0) minus the median age at death for the HIV-negative reference (75.0). 95% confidence intervals at 25th, 50th and 75th percentiles calculated using the delta method. Numbers on x-axis are deciles (years of age at death) for the reference group.

Comment in

References

    1. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362:1267–1274. - PubMed
    1. Wada N, Jacobson L, Cohen M, French AL, Phair JP, Muñoz A. Cause-specific life expectancies after age 35 for HIV-infected and HIV-negative individuals followed simultaneously in long-term cohort studies: 1984–2008. Am J Epidemiol. 2013;177:116–125. - PMC - PubMed
    1. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–129. - PubMed
    1. Palella FJ, Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138:620–626. - PubMed
    1. Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis. 2003;188:1659–1665. - PubMed

Publication types

Substances